



NMSB2

Bell Laboratories
600 Mountain Avenue
Murray Hill, NJ 07974-0636

June 12, 2008

U. S. Nuclear Regulatory Commission
Region I
475 Allendale Road
King of Prussia, PA 19406-1415

Licenses: 29-00170-03 (03005224)
SMB-1260 (04002472)

Subject: Submittal of Decommissioning Plan for Bell Laboratories- Division of
Lucent Technologies, Murray Hill, NJ

2008 JUN 17 AM 8:01

RECEIVED
REGION I

To Whom It May Concern:

Please find attached two copies of our decommissioning plan (DP) designed to achieve unrestricted release and termination of license numbers 29-00170-03 and SMB-1260. Formal notification of our intent to decommission was submitted on April 26, 2007. Notification was also submitted to the State of New Jersey Department of Environmental Protection (NJDEP). After decommissioning, Bell Laboratories - Division of Lucent Technologies will retain the site and decommissioned areas for future operations. Bell Laboratories - Division of Lucent Technologies will continue to use two self-shielded irradiators under NRC License # 29-00170-08.

Historical operations involved a variety of radionuclides for research. An overwhelming majority of the activity possessed at the site was confined to a very small footprint. Small amounts (microCi to milliCi quantities) of dispersible materials and reagents containing source materials were distributed to other laboratory areas for low level research activities. Research areas were routinely surveyed and maintained at low levels of residual surface activity (RG 1.86 limits). Starting in 1990, Bell Laboratories - Division of Lucent Technologies has drastically reduced the use of radioactive materials and conducted decommissioning activities (remediation and/or surveys) in areas of heavy usage. These decommissioning activities give us a high degree of confidence in the radiological status of impacted areas. The last receipt of radioactive materials was in 1999. All radioactive materials and wastes have been disposed, except for small quantities of source materials (high value crystals) that will be retained under a general license per the provisions of 10CFR40.22. Two small areas of residual activity on a floor surface (<1m²) will be remediated during decommissioning.

142518 / 142519


NMSS/RCN1 MATERIALS-002

Submittal of Decommissioning Plan for Bell Laboratories - Division of Lucent Technologies, Murray Hill, NJ/Page 2

Bell Laboratories - Division of Lucent Technologies requests a license amendment to incorporate the DP, which is based on site-specific Derived Concentration Guideline Levels (DCGLs). A site-specific dose model is used, not because of the complexity of the site or the nature of remedial actions anticipated, but because some of the nuclides possessed at the site are not listed in the DandD dose model and due to the overly-conservative screening values for alpha emitters.

I appreciate your time and efforts with this matter and look forward to working with you during the decommissioning process. If you have any questions or concerns, please contact me at 908-582-6049 or Richard Quick, RSO, at 908-582-5907.

Sincerely yours,



Barry Dambach
EH&S Vice-President

Enclosures:
Alcatel-Lucent Murray Hill Facility
Decommissioning Plan
Volumes 1 & 2

cc with Enclosures:
NRC Correspondence File

cc without Enclosures:
NJDEP
NJDEP Correspondence File
Radiation Safety Committee

This is to acknowledge the receipt of your letter/application dated

6/12/2008, and to inform you that the initial processing which includes an administrative review has been performed.

ENVIRONMENTAL ASSESSMENT 29-CD 70-03 / SM8-1260
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 142518/142519
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.